Core Points - The document outlines the internal reporting system for significant information at Shandong Weiming Bio-Pharmaceutical Co., Ltd, ensuring timely and accurate disclosure of information that may impact stock prices and investor rights [1][2][3] Group 1: Internal Reporting Obligations - The system mandates that individuals with reporting obligations must promptly report significant information to the chairman and board secretary [2][3] - Reporting obligations include directors, senior management, department heads, and significant shareholders [2][3] - The board secretary is responsible for organizing and coordinating information disclosure [2][3] Group 2: Definition of Significant Information - Significant information includes major meetings, transactions, litigation, changes, and risks that could affect stock prices [3][4] - Specific thresholds for reporting transactions are established, such as asset transactions exceeding 10% of total assets or significant revenue impacts [4][5] Group 3: Reporting Procedures - The reporting process requires immediate notification of significant events, with both verbal and written communication to the board secretary [29][30] - The board secretary must assess whether the information requires public disclosure and report to the board accordingly [30][31] Group 4: Responsibilities and Accountability - The board of directors oversees the internal reporting and external disclosure processes [32][33] - Individuals failing to meet reporting obligations may face disciplinary actions, including fines or termination [21][22] Group 5: Additional Reporting Requirements - The document specifies additional reporting for related party transactions, litigation, and significant operational changes [10][11][12] - Social responsibility incidents, such as environmental accidents, must also be reported [21]
ST未名: 《重大信息内部报告制度》(2025年7月)